Progression of HIV infection in the post-HAART era among a cohort of HIV + Greek haemophilia patients

Haemophilia

Volumn 11, Issue 4, 2005, Pages 360-365

  Katsarou, O ^a   Touloumi, G ^b   Antoniou, A ^b   Kouramba, A ^a   Hatzakis, A ^b   Karafoulidou, Anastasia ^a  

^a LAIKO GENERAL HOSPITAL   (Greece)

^b UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

HAART; Haemophilia; HIV; Mortality

Indexed keywords

ANTIRETROVIRUS AGENT; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ARTICLE; CANCER INCIDENCE; CAUSE OF DEATH; COHORT ANALYSIS; COMORBIDITY; CONTROLLED STUDY; DISEASE COURSE; FOLLOW UP; GREECE; HEMOPHILIA; HEPATITIS C; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIVER CANCER; MAJOR CLINICAL STUDY; MALE; NONHODGKIN LYMPHOMA; PNEUMOCYSTIS PNEUMONIA; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK ASSESSMENT; RISK REDUCTION; SEROCONVERSION;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CAUSE OF DEATH; CHILD; CHILD, PRESCHOOL; DISEASE PROGRESSION; GREECE; HEMOPHILIA A; HIV INFECTIONS; HIV-1; HUMANS; INCIDENCE; INFANT; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RISK FACTORS;

EID: 22744442911     PISSN: 13518216     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2516.2005.01109.x     Document Type: Article

References (38)

1. Mocroft A, Vella S, Benfield TL et al. Changing patterns of mortality across Europe in patients infected with HIV-1. Lancet 1998; 352: 1725-30.
2. Erb P, Battegay M, Zimmerli W, Rickenbach M, Egger M, for the Swiss HIV Cohort Study Effect of Antiretroviral Therapy on Viral Load, CD4 Cell Count, and Progression to Acquired Immunodeficiency Syndrome in a Community Human Immunodeficiency Virus-Infected Cohort. Arch Intern Med 2000; 160: 1134-40.
3. Palella FJ, Delaney KM, Moorman AC et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998; 338: 853-60.
4. Valdez H, Clowdhry TK, Asaad R et al. Changing speetrum of mortality due to human immunodeficiency virus: analysis of 260 deaths during 1995-1999. Clin infect Dis 2001; 32: 1487-93.
5. Bonnet F, Morlat P, Chene G et al. Causes of death among HIV - infected patients in the era of highly active antiretroviral therapy, Bordeaux, France, 1998-1999. HIV Med 2002; 3: 195-9.
6. Rosenthal E, Poiree M, Pradier C et al., for the GERMIVIC Joint Study Group Mortality due to hepatitis C-related liver disease in HIV-infected patients in France (Mortavic 2001 study). AIDS 2003; 17: 1803-9.
7. Goedert JJ, Kessler CM, Aledort LM et al. A prospective study of human immunodeficiency virus type 1 infection and the development of AIDS in subjects with hemophilia. N Engl J Med 1989; 321: 1141-8.
8. Sabin C, Phillips A, Elford J, Griffiths P, Janossay G, Lee C. The progression of HIV disease in a haemophilic cohort followed for 12 years. BJH 1993; 83: 330-3.
9. Darby SC, Ewart DW, Giangrande PLF, Spooner RJD, Rizza CR. Importance of age at infection with HIV-1 for survival and development of AIDS in UK haemophilia population. Lancet 1996; 347: 1573-9.
10. Touloumi G, Karafoulidou A, Gialeraki A et al. Determinants of Progression of HIV Infection in a Greek Hemophilia Cohort Followed for Up to 16 Years After Seroconversion. J Acq Imm Def Syndr Human Retrov 1998; 19: 89-97.
11. Merry C, McMahon C, Ryan M, O'Shea E, Mulcahy F, Smith OP. Successful use of protease inhibitors in HIV-infected haemophilia patients. BJH 1998; 101: 475-9.
12. Sabin CA, Yee TT, Devereux H et al. Two decades of HIV infection in a cohort of haemophilic individuals: clinical outcomes and response to highly active antiretroviral therapy. AIDS 2000; 14: 1001-7.
13. Prins M, Sabin C, Lee CA, Devereux H, Coutinho RA. Pre- AIDS mortality and its association with HIV disease progression in haemophilic men, injection drug users and homosexual men. AIDS 2000; 14: 1829-37.
14. Eyster ME, Diamondstone CS, Lien JM, Ehmann WC, Quart S, Goedert JJ. Natural history of hepatitits C virus infection in multitransfused hemophiliacs: effect of cionfection with human immunod virus. J AIDS 1993; 6: 602-10.
15. Sulkowski MS, Thomas DL, Chaisson RE, Moore RD. Hepatotoxicity associated with antiretroviral therapy in adults infected with human immunodeficiency virus and the role of hepatitis C or B virus infection. JAMA 2000; 283: 74-80.
16. Kalbfleisch JD, Prentice RL. The Statistical Analysis of Failure Time Data. New York: John Wiley and Sons, 1980.
17. Fine JP, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. J Am Statist Assoc 1999; 94: 496-509.
18. CASCADE collaboration. Changes over calendar time in the risk of specific first AIDS-defining events following HIV seroconversion, adjusting for competing risks. Int J Epidemiol 2002; 31: 951-8.
19. Lee CA, Phillips A, Elford J et al. The natural history of human immunodeficiency virus infection in a haemophilic cohort. Br J Haematol 1989; 73: 228-34.
20. Matthews GV, Bower M. Mandalia S. Poweles T. Nelson MR, Gazzard BG. Changes in acquired immunodeficiency syndrome-related lymphoma since the introduction of highly active antiretroviral therapy. Blood 2000; 96: 2730-4.
21. Levine AM, Seneviratne L. Espina BM et al. Evolving characteristics of AIDS-related lymphoma. Blood 2000; 96: 4084-90.
22. Moore RD, Chaisson RE. Natural history of HIV infection in the era of combination antiretroviral therapy. AIDS 1999; 13: 1933-42.
23. Kirk O. Pedersen C. Cozzi Lepri A et al. Non -Hodgkin lymphoma in HIV infected patients in the era of highly active antiretroviral therapy. Blood 2001; 98: 3406-12.
24. Besson C, Goubar A, Gabarre J et al. Changes in AIDS-related lymphoma since the era of highly active antiretroviral therapy. Blood 2001; 98: 2339-44.
25. Bica I, McGovern B, Dhar R et al. Increasing mortality due to End - Stage Liver Disease in Patients with Human Immunodeficiency Virus Infection. Clin Inf Dis 2001; 32: 492-7.
26. Louie JK, Hsu LC, Osmond DH, Katz MH, Schwarcz SK. Trends in causes of death among persons with Acquired Immunodeficiency Syndrome in the Era of Highly Active antiretroviral Therapy, San Francisco, 1994-1998. J Inf Dis 2002; 186: 1023-27.
27. Greub G, Ledergerber B, Battegay M et al. Clinical progression, survival and immune recovery during antiretroviral therapy in patients with HIV-1 and hepatitis C virus coinfection: the Swiss HIV Cohort Study. Lancet 2000; 356: 1800-5.
28. Ragni MV, Belle SH. Impact of human immunodeficiency virus infection on progression to end - stage liver disease in individuals with hemophilia and hepatitis C virus infection. J Infect Dis 2001; 183: 112-5.
29. Bica I, McGovern B, Stone D, Mc Gowan K, Scheib R, Snydman DR. Increasing mortality due to end - stage liver disease in patients with HIV infection. Clin Infect Dis 2001; 32: 492-7.
30. Graham CS, Baden LR, Yu E et al. Influence of human immunodeficiency virus infection of the course of hepatitis C virus infection: a meta-analysis. Clin Infect Dis 2001; 33: 562-9.
31. den Brinker M, Wit FW, Wertheim-van Dillen PM et al. Hepatitis B and C virus co-infection and the risk for hepatotoxicity of highly active antiretroviral therapy in HIV-1 infection. AIDS 2000; 14: 2895-902.
32. Nuner M, Lana R, Mendoza JL, Martin-Carbonero L, Soriano V. Risk factors for severe hepatic injurie after introduction of highly active antiretroviral therapy. J Acquir Immune Defic Syndr 2001; 27: 426-31.
33. Rodriguez-Rosado R, Garcia-Samaniego J, Soriano V. Hepatotoxicity after introduction of highly active antiretroviral therapy. AIDS 1998; 12(10): 1256.
34. John M, Flexman J, French MA. Hepatitis virus - associated hepatitis following treatment of HIV infected patients with HIV protease inhibitors: an immune restoration disease? AIDS 1998; 12: 2289-93.
35. Delladetsima J, Katsarou O, Touloumi G, Vgenopoulou S, Hatzakis A, Karafoulidou A. Significance of immune status, genotype and viral load in the severity of chronic hepatitis C in HIV infected haemophilia patients. Haemophilia 2002; 8: 668-73.
36. Sulkowski MS, Thomas DL, Mehta SH, Chaisson RE, Moore RD. Hepatotoxicity Associated with Nevirapine or Efavirenz - containing antiretroviral therapy: role of hepatitis C and B Infections. Hepatology 2002; 35: 182-9.
37. Harry R. Auzinger G. Wendon J. The clinical importance of Adrenal Insufficiency in acute hepatic dysfunction. Hepatology 2002; 36: 395-402.
38. Sen S. Williams R. Jalan R. The pathopysiological basis of acute-on-chronic liver failure. Liver 2002; 22(Suppl. 2): 5-13.